The discounted registered direct offering and concurrent placements create immediate dilution overhang. Traders should watch for the EGM in September for shareholder approval of warrants and the Australian Placement tranche. The stock may face continued pressure until the capital raise is fully absorbed and clinical catalysts emerge for RAD101.
Price Chart
Executive Summary
Radiopharm Theranostics announced a multi-tranche capital raise: a US$4.1M registered direct offering of 1,281,646 ADSs at $3.16/ADS (26% discount to last close) with concurrent warrants at $3.79, plus an A$6.7M Australian Placement and an A$6M Share Purchase Plan. The total proceeds (~US$13M) are allocated to the RAD101 registrational Phase 3 study and other pipeline programs. The dilutive impact is significant for the $45M market cap company, and the discounted pricing signals urgent capital needs for a pre-revenue biotech.
Key Facts
- Registered direct offering of 1,281,646 ADSs at $3.16/ADS, raising ~$4.1M gross proceeds
- Concurrent warrants to purchase up to 1,281,646 ADSs at $3.79/ADS, exercisable after shareholder approval
- Australian Placement of A$6.7M (US$4.7M) and Share Purchase Plan up to A$6M (US$4.2M)
- Proceeds to fund RAD101 registrational Phase 3 study and other clinical programs
- Shareholder approval required for warrants and portions of Australian Placement; EGM expected around September 11, 2026
Financial Impact
Dilution of ~1.28M ADSs (384M ordinary shares) at a 26% discount to the prior closing price of $4.29; potential full dilution from warrants could add another ~1.28M ADSs. Total gross proceeds across all tranches approximately US$13M, representing roughly 29% of the company's $45M market cap.
Risk Factors
- Shareholder approval not obtained for warrants or Australian Placement tranche
- Clinical trial failure or delay for RAD101 or other pipeline assets
- Further dilution from the Share Purchase Plan or future capital needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081559 |
| Document: ea029928601ex10-2.htm | 0001213900-26-081559 |
| Document: ea029928601ex99-1.htm | 0001213900-26-081559 |
| Document: ea0299286-6k_radiopharm.htm | 0001213900-26-081559 |
| Document: ea029928601ex5-1.htm | 0001213900-26-081559 |
| Document: 0001213900-26-081559-index-headers.html | 0001213900-26-081559 |
| Document: 0001213900-26-081559-index.html | 0001213900-26-081559 |
| Document: 0001213900-26-081559.txt | 0001213900-26-081559 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers